Agile Therapeutics (NASDAQ:AGRX) Stock Passes Below 200 Day Moving Average of $1.44

Shares of Agile Therapeutics, Inc. (NASDAQ:AGRX) crossed below its 200-day moving average during trading on Friday . The stock has a 200-day moving average of $1.44 and traded as low as $0.37. Agile Therapeutics shares last traded at $0.38, with a volume of 47,561 shares changing hands.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the company. StockNews.com assumed coverage on Agile Therapeutics in a report on Saturday. They set a “sell” rating for the company. Maxim Group reaffirmed a “hold” rating on shares of Agile Therapeutics in a report on Monday, March 18th.

Agile Therapeutics Trading Up 2.7 %

The firm has a market cap of $2.61 million, a PE ratio of -0.04 and a beta of 1.42. The stock has a fifty day simple moving average of $0.64 and a two-hundred day simple moving average of $1.44.

Institutional Trading of Agile Therapeutics

A number of large investors have recently modified their holdings of the business. Vanguard Group Inc. bought a new stake in shares of Agile Therapeutics during the 4th quarter valued at about $40,000. Armistice Capital LLC boosted its position in shares of Agile Therapeutics by 10.2% during the 4th quarter. Armistice Capital LLC now owns 108,000 shares of the specialty pharmaceutical company’s stock valued at $211,000 after acquiring an additional 10,000 shares during the last quarter. State Street Corp bought a new stake in shares of Agile Therapeutics during the 2nd quarter valued at about $32,000. Virtu Financial LLC bought a new stake in shares of Agile Therapeutics during the 4th quarter valued at about $32,000. Finally, BlackRock Inc. boosted its position in shares of Agile Therapeutics by 538.6% during the 3rd quarter. BlackRock Inc. now owns 303,799 shares of the specialty pharmaceutical company’s stock valued at $91,000 after acquiring an additional 256,227 shares during the last quarter. Institutional investors own 10.92% of the company’s stock.

Agile Therapeutics Company Profile

Agile Therapeutics, Inc, a women's healthcare company, researches, develops, and commercializes prescription contraceptive products for women in the United States. Its lead product is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch. The company is also developing a pipeline of Twirla line extensions and other products, including AG200-15 Extended Regimen (ER), a regimen that allows a woman to have four episodes of withdrawal bleeding per year; AG200-15 smaller patch (SmP), which is a regimen designed to provide shorter and lighter withdrawal bleeds, and enhance contraceptive efficacy; AG200-15 ER SmP, a regimen to allow a woman to extend the length of her contraceptive cycle, as well as have shorter and lighter withdrawal bleeding episodes per year; and P-Patch, a progestin-only contraceptive patch intended for use by women who are unable or unwilling to take estrogen.